Drug lookup
Drug reference

Demeclocycline

Tetracycline · Antibiotic

Also known as Demeclocycline hydrochloride, Demethylchlortetracycline, Ledermycin

TetracyclineAntibiotic
CDSCO approved
EXCRETION
not curated
INTERACTIONS
8 major
SEVERE in our sources
PREGNANCY
Should not be given to pregnant women. Effects on skeletal development have been documented in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth, and maternal hepatotoxicity has been reported with large parenteral doses.
FDA category + note
Top interactionssee all 9
  • AcitretinSevereDatabaseDDInter
  • Aminolevulinic AcidSevereDatabaseDDInter
  • IsotretinoinSevereDatabaseDDInter
  • LomitapideSevereDatabaseDDInter

Mechanism

Demeclocycline is a tetracycline antimicrobial drug. As an antibiotic, it is presumed to inhibit bacterial protein synthesis, although the specific mechanism for demeclocycline is not detailed in the excerpts. It also attenuates the antidiuretic effects of vasopressin, likely by decreasing the accumulation and action of cyclic AMP, though the full mechanism for this interference is not completely determined.

Indications

Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)Severe infections (including refractory urinary-tract infections)Acute sinusitisAcute cough (if systemically very unwell or at higher risk of complications)Community-acquired pneumoniaHospital-acquired pneumoniaSyndrome of inappropriate ADH secretion (SIADH)Hyponatremia secondary to excessive ADH secretion in congestive heart failure (CHF) patients on diureticsTumor-Associated Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

Dosing

Adult
Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma): Initially 200 mg daily in 1–2 divided doses for 1 day, then maintenance 100 mg daily. Severe infections (including refractory urinary-tract infections): 200 mg daily.…
Pediatric
Child 12–17 years (Susceptible infections, e.g. chlamydia, rickettsia and mycoplasma): Initially 200 mg daily in 1–2 divided doses for 1 day, then maintenance 100 mg daily. Child 12–17 years (Severe infections, including refractory urinary-tract infections): 200 mg daily.…
Renal adjustment
Dose has to be reduced in renal failure.
Hepatic adjustment
Manufacturers generally advise caution.

Pharmacokinetics

Bioavailability
Incompletely absorbed from gastrointestinal tract; absorption is better if taken in empty stomach.
Protein binding
Variable degree of protein binding.
Excretion
Primarily excreted in urine by glomerular filtration.

Contraindications

  • Pregnant women
  • Breast-feeding women

Side effects

Common
DizzinessTooth discolourationEpigastric painNauseaVomitingDiarrhoeaOral disordersHeadacheVisual disturbancesphototoxic photosensitivity (sunburn-like erythema, edema, blistering)
Serious
  • Fontanelle bulging (in infants)
  • Haemolytic anaemia
  • Hepatic disorders
  • Idiopathic intracranial hypertension
  • Increased risk of infection
  • Neutropenia
  • Pancreatitis
  • Pseudomembranous enterocolitis
  • Stevens-Johnson syndrome
  • Thrombocytopenia

Pregnancy & lactation

Pregnancy

Should not be given to pregnant women. Effects on skeletal development have been documented in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth, and maternal hepatotoxicity has been reported with large parenteral doses.

Lactation

Should not be given to women who are breast-feeding (although absorption and therefore discoloration of teeth in the infant is probably usually prevented by chelation with calcium in milk).

Drug interactions

Acitretin
Severe
Database

Clinical effect not specified

Source: DDInter

Aminolevulinic Acid
Severe
Database

Clinical effect not specified

Source: DDInter

Isotretinoin
Severe
Database

Clinical effect not specified

Source: DDInter

Lomitapide
Severe
Database

Clinical effect not specified

Source: DDInter

Methoxyflurane
Severe
Database

Clinical effect not specified

Source: DDInter

Mipomersen
Severe
Database

Clinical effect not specified

Source: DDInter

Tretinoin
Severe
Database

Clinical effect not specified

Source: DDInter

Vitamin A
Severe
Database

Clinical effect not specified

Source: DDInter

Desmopressin
Moderate
Database

Reduced effectiveness of desmopressin.

Not explicitly stated, but implies monitoring for therapeutic effect.

Source: DDInter

3 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.

Related guidelines

Other Tetracycline drugs

Ask House about Demeclocycline

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Harrison 22e, Katzung, BNF·Verified: 2026-05-13 · House clinical team